BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37828515)

  • 21. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
    Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
    Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer.
    Gao X; Liang J; Wang L; Zhang Z; Yuan P; Wang J; Gao Y; Ma F; Calagua C; Ye H; Voznesensky O; Wang S; Wang T; Liu J; Chen S; Liu X
    Mol Oncol; 2021 Jul; 15(7):1901-1920. PubMed ID: 33932081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
    Vander Griend DJ; Litvinov IV; Isaacs JT
    Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
    Yin Y; Liu Q; Shao Y; He X; Zhu Q; Lu S; Liu P
    Prostate; 2022 Jan; 82(1):26-40. PubMed ID: 34591337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
    Yoon HG; Wong J
    Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amplitude modulation of androgen signaling by c-MYC.
    Ni M; Chen Y; Fei T; Li D; Lim E; Liu XS; Brown M
    Genes Dev; 2013 Apr; 27(7):734-48. PubMed ID: 23530127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells.
    Lee JG; Zheng R; McCafferty-Cepero JM; Burnstein KL; Nanus DM; Shen R
    Mol Carcinog; 2009 Feb; 48(2):141-9. PubMed ID: 18623111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha.
    Ko S; Shi L; Kim S; Song CS; Chatterjee B
    Mol Endocrinol; 2008 Feb; 22(2):273-86. PubMed ID: 17975021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer.
    Tan JA; Bai S; Grossman G; Titus MA; Harris Ford O; Pop EA; Smith GJ; Mohler JL; Wilson EM; French FS
    Mol Cell Endocrinol; 2014 Jan; 382(1):302-313. PubMed ID: 24103312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
    Li M; Liu M; Han W; Wang Z; Han D; Patalano S; Macoska JA; Balk SP; He HH; Corey E; Gao S; Cai C
    Cancer Res; 2023 May; 83(10):1684-1698. PubMed ID: 36877164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
    Wu D; Sunkel B; Chen Z; Liu X; Ye Z; Li Q; Grenade C; Ke J; Zhang C; Chen H; Nephew KP; Huang TH; Liu Z; Jin VX; Wang Q
    Nucleic Acids Res; 2014 Apr; 42(6):3607-22. PubMed ID: 24423874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
    Jin F; Fondell JD
    Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
    Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
    Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
    Vatapalli R; Sagar V; Rodriguez Y; Zhao JC; Unno K; Pamarthy S; Lysy B; Anker J; Han H; Yoo YA; Truica M; Chalmers ZR; Giles F; Yu J; Chakravarti D; Carneiro B; Abdulkadir SA
    Nat Commun; 2020 Aug; 11(1):4153. PubMed ID: 32814769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent Prostate Cancer Cells.
    Chen Y; Han L; Dufour CR; Alfonso A; Giguère V
    Mol Cancer Res; 2024 Feb; 22(2):113-124. PubMed ID: 37889103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
    Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
    PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.